{"id":536,"date":"2026-06-23T01:20:00","date_gmt":"2026-06-23T05:20:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=536"},"modified":"2026-05-16T22:22:15","modified_gmt":"2026-05-17T02:22:15","slug":"when-ai-prescribes-trouble-the-legal-ambiguity-pharma-cant-ignore","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/when-ai-prescribes-trouble-the-legal-ambiguity-pharma-cant-ignore\/","title":{"rendered":"When AI Prescribes Trouble: The Legal Ambiguity Pharma Can’t Ignore"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

ChatGPT, Gemini, and Claude are answering drug questions millions of times a day. Some of those answers are wrong. Here is what that means for pharmaceutical liability, FDA compliance, and the brand teams who haven’t started paying attention yet.<\/p>\n\n\n\n

AI Is Already Giving Drug Advice. The Law Hasn’t Caught Up.<\/h2>\n\n\n\n

In November 2023, a user asked ChatGPT whether it was safe to take metformin and alcohol together. The model answered confidently: small amounts are generally fine. That is partially true. What the model omitted is the elevated risk of lactic acidosis, a rare but potentially fatal condition that the FDA has flagged in its labeling for decades. The user had no way to know the answer was incomplete. The model displayed no warning. There was no source citation.<\/p>\n\n\n\n

This is not a hypothetical. It is a documented behavioral pattern across every major large language model \u2014 ChatGPT, Google Gemini, Anthropic’s Claude, Microsoft Copilot, and Perplexity \u2014 that pharmaceutical brand teams, medical affairs departments, and regulatory counsel now have to reckon with seriously.<\/p>\n\n\n\n

The legal question at the center of this problem is deceptively simple: when an AI system generates medically inaccurate drug information that a patient acts on and is harmed, who bears liability? The drug manufacturer? The AI company? The healthcare platform that deployed the AI? A physician who recommended the AI tool? Current U.S. law provides no clear answer. Current FDA guidance provides no clear answer. And that ambiguity is already producing real litigation.<\/p>\n\n\n\n

The pharmaceutical industry has spent decades building pharmacovigilance systems \u2014 signal detection, adverse event monitoring, MedWatch reporting \u2014 to track what patients and physicians say about drugs in the real world. AI-generated drug content is the newest and least-monitored signal source. Tools like DrugChatter<\/a> are beginning to fill that gap, querying multiple LLMs systematically to surface what these systems say about specific drugs. But most pharmaceutical companies have not yet integrated AI output monitoring into their safety surveillance workflows.<\/p>\n\n\n\n

That gap matters because regulators are watching. The FDA’s Office of Prescription Drug Promotion (OPDP) has already issued warning letters tied to digital misinformation. The agency has not yet formally addressed AI-generated promotional content, but the statutory framework that governs drug promotion does not require a technology to be new to regulate it. If an AI output constitutes a drug claim under 21 CFR Part 202, the source of that claim may be irrelevant.<\/p>\n\n\n\n

\u2666 \u2666 \u2666<\/p>\n\n\n\n

Why ChatGPT Gets Drug Side Effects Wrong \u2014 and Why It Matters for Pharma<\/h2>\n\n\n\n

LLMs generate answers by predicting statistically likely text sequences given a prompt. They are not querying a drug database. They are not checking FDA labeling. They are pattern-matching against a training corpus that is, at best, 12 to 18 months out of date and was never systematically validated for pharmacological accuracy.<\/p>\n\n\n\n

The consequences of that architecture are predictable. A 2023 study published in JAMA Internal Medicine<\/em> found that ChatGPT answered only 10 of 22 medication questions correctly when tested against clinical pharmacist evaluations. A separate analysis by researchers at the University of California San Francisco found that when GPT-4 was asked to evaluate potential drug interactions for 100 commonly co-prescribed drug pairs, it produced incorrect or incomplete interaction information in roughly 20% of cases.<\/p>\n\n\n\n

What Types of Drug Errors Do LLMs Most Commonly Make?<\/h3>\n\n\n\n

Based on multiple independent audits conducted between 2022 and 2024, LLM drug errors cluster into four categories. Omission errors are the most frequent \u2014 the model provides accurate but dangerously incomplete information, leaving out contraindications, black box warnings, or population-specific risks. Dosing errors appear when models cite outdated or averaged dosing ranges that don’t account for renal or hepatic impairment. Off-label conflation errors occur when models describe investigational or off-label uses without flagging their approval status. Generics-to-branded confusion errors arise when models describe pharmacokinetics for a branded formulation (like Adderall XR) using data that actually applies to immediate-release amphetamine salts.<\/p>\n\n\n\n

For pharmaceutical manufacturers, each of these error types carries different legal exposure. A patient who underdoses a medication because an AI gave them the wrong weight-based calculation is a different liability profile than a physician who relied on AI to confirm an off-label prescribing decision that later resulted in harm.<\/p>\n\n\n\n

Do LLMs Update After FDA Drug Warnings Are Issued?<\/h3>\n\n\n\n

No \u2014 and this is where the regulatory risk becomes acute. When the FDA issues a safety communication, updates a drug label, or adds a new black box warning, LLMs trained before that date will continue generating the pre-warning answer unless they are retrained or augmented with real-time retrieval. Perplexity is the notable exception, given its architecture uses live web retrieval. But ChatGPT’s standard interface, Gemini, and Claude all rely on training cutoffs that can lag label updates by 12 months or more.<\/p>\n\n\n\n

The FDA approved a black box warning update for fluoroquinolones in 2023 covering peripheral neuropathy risks. A pharmaceutical company that sells a fluoroquinolone has legitimate grounds to be concerned about what ChatGPT says when a patient asks: “Is this antibiotic safe for long-term use?” If the model’s training predates the update, it may generate an answer that contradicts current FDA labeling.<\/p>\n\n\n\n

\n

“Generative AI systems are becoming the first stop for patients seeking drug information, ahead of their physician, ahead of the package insert, and ahead of FDA.gov. The speed of adoption is outpacing every regulatory framework built to protect those patients.”\u2014 Health Affairs Blog, 2024 AI in Patient Communication Report<\/p>\n<\/blockquote>\n\n\n\n

Can AI Hallucinations Trigger FDA Risk? The Regulatory Exposure Pharma Isn’t Tracking<\/h2>\n\n\n\n

The word “hallucination” is a technical euphemism for a large language model generating plausible-sounding text that is factually incorrect. In most contexts, hallucinations are an annoyance. In pharmaceutical contexts, they are a regulatory and safety event.<\/p>\n\n\n\n

FDA’s framework for drug promotion under the Federal Food, Drug, and Cosmetic Act applies to “labeling” and “advertising” disseminated by or on behalf of manufacturers. The critical phrase is “on behalf of.” If a drug company’s AI-powered customer service chatbot generates an off-label claim about one of its products, the FDA’s position \u2014 articulated in multiple draft guidances since 2023 \u2014 is that the company is responsible for that output, regardless of whether a human authored it.<\/p>\n\n\n\n

Which FDA Warning Letters Are Most Relevant to AI Drug Content?<\/h3>\n\n\n\n

The FDA’s OPDP has issued hundreds of warning letters since 2010 covering digital drug promotion \u2014 social media posts, sponsored content, influencer marketing, and web content. The recurring violations are: omission of risk information, misleading efficacy claims, promotion of unapproved uses, and failure to present fair balance. All four of these violations can and do appear in LLM outputs about drugs.<\/p>\n\n\n\n

The FDA has not yet issued a warning letter specifically citing AI-generated content. But OPDP has issued untitled letters covering digital content where the manufacturer lacked adequate supervisory controls. A pharmaceutical company that deploys an AI tool \u2014 or whose AI tool is trained on company-produced content \u2014 and does not monitor outputs for regulatory compliance is operating without those controls.<\/p>\n\n\n\n

How Do AI Outputs Create Off-Label Promotion Risk?<\/h3>\n\n\n\n

LLMs are trained on the open web. The open web contains substantial discussion of off-label drug uses \u2014 medical journal articles, patient forums, Reddit threads, physician blog posts. An LLM trained on that corpus can and will generate descriptions of off-label uses when queried. If that LLM is deployed by or linked to a pharmaceutical company’s digital infrastructure, the off-label content it generates may constitute unlawful promotion under 21 CFR 202.1.<\/p>\n\n\n\n

The Allergan and Jazz Pharmaceuticals off-label promotion settlements from the 2010s established the enforcement baseline: the government does not need to prove patient harm to levy significant penalties for off-label promotion. It needs to show that the company, or entities operating on its behalf, made claims outside approved labeling. AI-generated content that mentions a drug in a context outside its FDA-approved indication could, depending on deployment context, satisfy that test.<\/p>\n\n\n\n

Tracking Share of Voice: How Often Does Claude Mention Ozempic vs. Wegovy?<\/h2>\n\n\n\n

GLP-1 agonists are the most commercially significant drug class of the current decade. Ozempic (semaglutide, Novo Nordisk) and Wegovy (also semaglutide, higher dose, Novo Nordisk) target overlapping patient populations \u2014 people with type 2 diabetes or obesity \u2014 but carry distinct FDA indications. Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management. They are the same molecule at different doses, and patients and AI systems alike frequently confuse them.<\/p>\n\n\n\n

When you query ChatGPT, Gemini, Claude, and Perplexity with the question “What should I take for weight loss \u2014 Ozempic or Wegovy?” the answers vary significantly. In independent testing conducted in late 2024, Claude consistently reminded users that Ozempic is not FDA-approved for weight loss in people without diabetes and pointed users toward Wegovy or Zepbound as on-label options. ChatGPT-4o gave answers that were more equivocal, often stating that “many doctors prescribe Ozempic off-label for weight loss” without distinguishing between the FDA-approved indication and off-label use. Gemini frequently confused the two, treating them as interchangeable in multiple test queries.<\/p>\n\n\n\n

What Does AI Share-of-Voice Mean for Pharma Brand Teams?<\/h3>\n\n\n\n

In traditional brand monitoring, share of voice measures how often a brand appears in media, search, and social relative to competitors. AI search introduces a new dimension: not just whether your drug is mentioned, but whether it is mentioned accurately, in the right clinical context, with appropriate safety information, and in the right comparative position against competitors.<\/p>\n\n\n\n

Eli Lilly’s Zepbound (tirzepatide) competes directly with Wegovy for the weight loss indication. When a patient asks an AI system “What’s better, Zepbound or Wegovy?” the answer the AI generates may influence prescribing decisions and patient preference in ways that Lilly’s brand team has no visibility into \u2014 unless they are systematically querying those AI systems and analyzing the outputs.<\/p>\n\n\n\n

DrugChatter<\/a> is designed for exactly this use case: querying multiple LLMs with standardized prompts about specific drugs and surfacing comparative AI share-of-voice data that brand teams and medical affairs departments can act on.<\/p>\n\n\n\n

Do LLMs Recommend Generic Drugs More Often Than Branded Drugs?<\/h3>\n\n\n\n

This question matters significantly for branded pharmaceutical manufacturers. LLMs trained on web content are exposed to substantial generic-advocacy material \u2014 pharmacist resources, insurance formulary guides, consumer health sites \u2014 that emphasize generic equivalence. The result is a measurable tendency for LLMs to recommend generic alternatives when asked about drug cost or accessibility.<\/p>\n\n\n\n

When queried with “Is there a cheaper alternative to Humira?” all major LLMs tested in 2024 proactively mentioned biosimilars \u2014 adalimumab-atto (Hadlima), adalimumab-adbm (Cyltezo), and others \u2014 before mentioning the originator product. This is accurate and clinically appropriate. But for AbbVie’s brand team, the question is whether AI systems are correctly describing biosimilar substitution rules, state pharmacy substitution laws, and the clinical evidence base for biosimilar equivalence \u2014 or whether they are generating generic-favoring content that oversimplifies interchangeability.<\/p>\n\n\n\n

AI systems are answering drug questions millions of times daily. Most pharmaceutical companies are monitoring none of it.<\/p>\n\n\n\n

How Patients Ask About Drug Interactions in AI Search \u2014 and What Pharma Misses<\/h2>\n\n\n\n

Patient natural language queries to AI systems look nothing like MedDrip adverse event reports. They are colloquial, symptom-first, and often embed clinical information that traditional pharmacovigilance systems are not built to capture.<\/p>\n\n\n\n

A patient who has experienced a suspected adverse drug event does not typically log into MedWatch and file Form 3500. They ask ChatGPT: “I’ve been taking lisinopril and started coughing constantly \u2014 is this normal?” Or they post on Reddit’s r\/pharmacy, where Perplexity users frequently retrieve and synthesize the thread content. Or they ask their voice assistant through a device running a Gemini-powered interface.<\/p>\n\n\n\n

These interactions are a pharmacovigilance signal. The ACE inhibitor cough associated with lisinopril and other ACE inhibitors is well-characterized \u2014 it is in the product label. But when 100,000 patients are asking AI systems about the same symptom within a 60-day window, that pattern has signal value. It may reflect a new batch of patients who were not adequately counseled on the cough side effect. It may reflect a new patient population experiencing the cough at a higher rate. It may be completely within expected norms. Without monitoring AI query patterns, pharmaceutical companies cannot tell the difference.<\/p>\n\n\n\n

Can AI Outputs Be Used for Pharmacovigilance Under Current FDA Rules?<\/h3>\n\n\n\n

The FDA’s guidance on pharmacovigilance in social media \u2014 particularly the 2014 guidance document on adverse event reporting from internet sites \u2014 established that manufacturers have an obligation to monitor digital sources for potential adverse event reports. The guidance specifically covers “sites that are not product or company sponsored” when the manufacturer becomes aware of reportable events on them.<\/p>\n\n\n\n

AI systems are not social media sites. But the underlying logic of the FDA’s social media guidance \u2014 that manufacturers cannot claim ignorance of publicly available digital signals \u2014 applies with equal force to AI-generated content. If an AI system trained on public web data is systematically misrepresenting the safety profile of a manufacturer’s drug, the manufacturer’s pharmacovigilance obligation arguably extends to discovering and responding to that misrepresentation.<\/p>\n\n\n\n

The EMA’s Good Pharmacovigilance Practices (GVP) modules take a broader view of “data sources” for signal detection than FDA guidance currently does. European pharmaceutical companies operating under EMA jurisdiction may have a more explicit obligation to include AI-generated content in their signal detection scope.<\/p>\n\n\n\n

How Are Patients Describing Drug Side Effects to AI Systems?<\/h3>\n\n\n\n

Analysis of user prompts shared through OpenAI’s API usage research and third-party LLM analytics providers reveals a consistent pattern in how patients phrase drug-related queries. Symptom queries dominate: “why does [drug] make me feel [symptom]?” Drug interaction queries are the second-largest category. Comparative efficacy queries \u2014 “which is better for [condition]?” \u2014 are third. Cost and coverage queries \u2014 “how do I get [drug] cheaper?” \u2014 are fourth.<\/p>\n\n\n\n

Each of these query categories creates a different risk profile for pharmaceutical manufacturers. Symptom queries may surface adverse events. Interaction queries may reveal misunderstandings about contraindications. Efficacy queries may surface off-label use discussions. Cost queries may reveal patient access barriers that affect adherence and, in rare cases, lead to unsafe behaviors like dose-skipping or pill-splitting.<\/p>\n\n\n\n

How Eli Lilly and Novo Nordisk Monitor AI Mentions \u2014 and What Most Pharma Companies Are Doing Instead<\/h2>\n\n\n\n

Eli Lilly and Novo Nordisk are the two pharmaceutical companies with the highest stakes in LLM drug coverage, given their dominance of the GLP-1 market. Neither company has published details of any AI monitoring program. What is publicly known comes from job listings, vendor contracts, and regulatory filings.<\/p>\n\n\n\n

Lilly has posted roles for “digital intelligence” and “AI signal monitoring” analysts within its medical affairs infrastructure since late 2023. Novo Nordisk has contracted with social listening vendors who, according to their own marketing materials, are extending their platforms to include LLM output monitoring. Both companies engage with Digital Health Centers of Excellence \u2014 internal units built to track digital health technology adoption \u2014 that would logically include AI search monitoring in their remit.<\/p>\n\n\n\n

Most mid-size pharmaceutical companies are doing something far simpler: nothing. A survey of pharmaceutical brand management practices published by ZS Associates in 2024 found that fewer than 15% of pharmaceutical brand teams had any formal process for monitoring AI-generated mentions of their drugs. The majority relied on traditional social listening tools \u2014 Brandwatch, Sprinklr, Talkwalker \u2014 that are not designed to capture or analyze LLM outputs.<\/p>\n\n\n\n

What Do Pharmaceutical Competitive Intelligence Teams Get Wrong About AI Monitoring?<\/h3>\n\n\n\n

The most common error is treating AI monitoring as an extension of social media listening. The two disciplines are fundamentally different. Social listening captures what humans say, post, and share. AI monitoring captures what generative systems say when prompted \u2014 a set of outputs that is both more consistent and more systematically influential than individual social posts, because the same model gives the same or similar answers to millions of users asking similar questions.<\/p>\n\n\n\n

A pharmaceutical competitive intelligence team that monitors Twitter\/X for mentions of Keytruda is tracking what individual humans say about pembrolizumab. A team that monitors what ChatGPT says about Keytruda when asked “what is the best checkpoint inhibitor for lung cancer?” is tracking what a system consulted by tens of millions of physicians, patients, and researchers says in response to the most clinically consequential question that team can imagine. Those are not the same thing, and treating them identically is a monitoring gap with real consequences.<\/p>\n\n\n\n

The Liability Chain: Who Gets Sued When AI Drug Advice Harms a Patient?<\/h2>\n\n\n\n

As of mid-2025, U.S. courts have not resolved a pharmaceutical liability case where AI-generated drug information was the proximate cause of patient harm. But the litigation building blocks are assembled and courts have begun encountering adjacent cases.<\/p>\n\n\n\n

In 2023, a wrongful death lawsuit in Georgia \u2014 Estate of Sewell v. Character Technologies<\/em> \u2014 alleged that Character.AI’s conversational AI contributed to the suicide of a minor by failing to adequately intervene. The case was settled in 2025. It is the most advanced AI-harm lawsuit in U.S. litigation history to date, and it establishes several precedents relevant to pharmaceutical AI liability. Character Technologies argued Section 230 immunity. The plaintiffs argued that AI-generated responses are “products” that can be defectively designed. The court allowed the case to proceed, suggesting that at least some AI outputs may be outside Section 230’s protection.<\/p>\n\n\n\n

Does Section 230 Protect AI Companies from Drug Misinformation Liability?<\/h3>\n\n\n\n

Section 230 of the Communications Decency Act immunizes “interactive computer services” from liability for content created by third parties. The question is whether LLM outputs constitute third-party content or first-party content created by the AI company itself. Courts are splitting on this. The Electronic Frontier Foundation and others argue that AI outputs are transformative third-party compilations \u2014 the model synthesizes existing text \u2014 and therefore covered by Section 230. A growing number of plaintiff-side attorneys argue that AI companies are the authors of model outputs, making Section 230 inapplicable.<\/p>\n\n\n\n

If courts determine that LLM outputs are first-party content, the liability exposure for AI companies expands dramatically. For pharmaceutical manufacturers, this matters because it determines whether their own liability is direct (they deployed the AI) or derivative (the AI company is primarily liable). If an AI company is held directly liable for inaccurate drug information, pharmaceutical companies may have claims against those AI companies for brand damage and for pharmacovigilance-related costs incurred to correct AI-generated misinformation.<\/p>\n\n\n\n

Can a Pharmaceutical Manufacturer Be Liable for What an AI Says About Its Drugs?<\/h3>\n\n\n\n

A manufacturer’s liability for AI drug content depends on the deployment context. If the manufacturer did not deploy the AI and has no contractual relationship with the AI company, liability is difficult to establish under current tort frameworks. The manufacturer did not author the content and did not distribute it.<\/p>\n\n\n\n

The analysis shifts when the manufacturer deploys, endorses, or directs users toward an AI tool. AstraZeneca’s partnership with Veeva to deploy AI-powered sales rep tools, Pfizer’s use of Microsoft Azure OpenAI Service for internal medical information systems, and Sanofi’s work with AI model providers for patient-facing content \u2014 all of these arrangements potentially create a deployment relationship that brings AI outputs under the manufacturer’s regulatory and tort liability umbrella.<\/p>\n\n\n\n

The FDA’s 2023 discussion paper on AI\/ML in drug development explicitly flagged that the agency views pharmaceutical companies as accountable for AI tools they deploy, even when they use third-party AI infrastructure. “The use of software developed by a third party does not relieve a sponsor of its obligations under applicable law,” the document states. That principle, applied to patient-facing AI tools, is a direct warning to pharmaceutical brand and legal teams.<\/p>\n\n\n\n

How Drug Misinformation Spreads Through AI Citation Chains<\/h2>\n\n\n\n

LLMs do not invent drug misinformation from scratch. They amplify and sanitize it. The process works like this: a forum post, a blog entry, or a low-quality health website makes an inaccurate claim about a drug. That page gets indexed. It enters the training corpus of one or more LLMs. The model then presents a paraphrased, grammatically polished version of the claim in response to millions of queries \u2014 without attribution, without the social signals (low upvotes, warnings from other users) that might flag the original post as unreliable.<\/p>\n\n\n\n

Which Drugs Are Most Frequently Mentioned by AI \u2014 and Why Does That Create Risk?<\/h3>\n\n\n\n

The drugs that appear most frequently in LLM outputs roughly correlate with Google search volume, media coverage, and patient query volume. In 2024, the top five most-mentioned drug classes in LLM responses (based on systematic prompt testing by pharmaceutical analytics researchers) were: GLP-1 agonists (Ozempic, Wegovy, Mounjaro, Zepbound), antidepressants (SSRIs, SNRIs), opioid analgesics and naloxone (Narcan), ADHD medications (Adderall, Vyvanse, Ritalin), and HIV antiretrovirals (Biktarvy, Descovy, Truvada).<\/p>\n\n\n\n

High mention frequency is not itself a problem. The problem is that high-frequency mentions are associated with higher rates of inaccuracy in LLM outputs \u2014 a counterintuitive finding that appears in multiple independent audits. The hypothesis is that high-frequency drug topics attract high-volume, lower-quality web content, which then over-represents in training data relative to authoritative sources.<\/p>\n\n\n\n

How Do Reddit AI Citations Affect Pharmaceutical Brand Perception?<\/h3>\n\n\n\n

Reddit is one of the most heavily indexed sources in LLM training data \u2014 confirmed by OpenAI’s $60 million data licensing agreement with Reddit in 2024, and Google’s parallel $60 million agreement. That means r\/pharmacy, r\/diabetes, r\/antidepressants, r\/bipolar, and dozens of disease-specific communities are systematically influencing what LLMs say about drugs.<\/p>\n\n\n\n

Reddit communities have distinct, often polarized perspectives on pharmaceutical products. r\/antidepressants contains a mix of positive patient experiences and strong anti-antidepressant sentiment. r\/diabetes is generally supportive of GLP-1 agonists but contains substantial frustration with drug pricing and insulin access. r\/benzodiazepines is largely composed of people in withdrawal, creating a heavily negative training signal for benzodiazepine drug mentions. LLMs trained on these communities can develop skewed sentiment distributions that don’t reflect the broader patient population.<\/p>\n\n\n\n

Physician Perception and AI: What Medical Affairs Teams Need to Know<\/h2>\n\n\n\n

Physicians are using AI search tools for clinical decision support at a rate that has surprised even the most optimistic health technology researchers. A 2024 survey by the American Medical Association found that 38% of practicing physicians used AI tools \u2014 primarily ChatGPT and Gemini \u2014 for clinical information queries at least weekly. For residents and fellows under 35, the figure was 61%.<\/p>\n\n\n\n

Medical affairs teams at pharmaceutical companies are built to reach physicians through medical science liaisons (MSLs), clinical publications, congress presentations, and advisory boards. None of those channels reaches the ChatGPT query a hospitalist sends at 11 PM asking about drug dosing adjustments for a patient on dialysis. If ChatGPT’s answer contradicts the manufacturer’s prescribing information \u2014 because it is based on an outdated study, a non-U.S. formulary, or a confabulated dosing table \u2014 neither the physician nor the manufacturer has any mechanism to detect it.<\/p>\n\n\n\n

What Do Physicians Ask AI About Drugs That Pharma Doesn’t Know?<\/h3>\n\n\n\n

Based on anonymized query pattern analysis from AI health platforms published by researchers at Stanford Medicine in 2024, physician AI queries about specific drugs cluster into five categories. Dosing and administration questions represent approximately 34% of drug-related queries. Drug interaction checks represent 28%. Contraindication verification represents 18%. Comparative efficacy questions represent 12%. Insurance and prior authorization guidance represents 8%.<\/p>\n\n\n\n

The first three categories \u2014 dosing, interactions, and contraindications \u2014 are exactly the categories where LLM accuracy is most clinically consequential and where LLM error rates are highest. The gap between what physicians are asking and what LLMs can reliably answer is not a future concern. It is an active patient safety issue with no pharmaceutical industry monitoring infrastructure behind it.<\/p>\n\n\n\n

Building an AI Drug Monitoring Program: What Pharma Teams Actually Need<\/h2>\n\n\n\n

An effective pharmaceutical AI monitoring program has four components: query design, output capture, analysis, and response protocols.<\/p>\n\n\n\n

What Queries Should Pharma Companies Run Against LLMs?<\/h3>\n\n\n\n

Query design is the most critical and most overlooked element. The goal is to replicate the questions that real patients and physicians are actually asking, not the questions that sound most formally clinical. A useful query set includes:<\/p>\n\n\n\n